Business Wire

Belkin Reengineers BOOSTCHARGE PRO 3-in-1 Wireless Charging Stand for Apple Watch Series 7 and iPhone 13

Share

Belkin, a consumer electronics leader, today announced the revamped BOOSTCHARGE PRO 3-in-1 Wireless Charging Stand upgraded to support fast charging on Apple Watch Series 7, which charges from 0 to 80% in about 45 minutes, up to 33% faster than Series 6**. In a familiar form factor to the product launched in 2020, this upgraded version will deliver the same functionality to iPhone 13 and iPhone 12 models, AirPods Pro and AirPods with Wireless Charging Case.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005013/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BOOSTCHARGE PRO 3-in-1 Wireless Charging Stand (Photo: Business Wire)

Key features:

  • Supports fast charging for Apple Watch Series 7
  • "Made for MagSafe” engineered to provide up to 15W of charging power to iPhone 13 and iPhone 12 models***
  • Provides 5W charging power for AirPods Pro and AirPods with Wireless Charging Case
  • MagSafe stand for iPhone features a non-slip design to support iPhone 13 or iPhone 12 models in portrait or landscape mode and is compatible with MagSafe cases up to 3mm thick
  • Includes 2-year warranty and Belkin Connected Equipment Warranty up to $2,500
  • Includes 40W power supply unit

AVAILABILITY AND PRICING

Available in Apple stores (Americas and Asia) in June
Available in Apple stores (EMEA and Australia / New Zealand) in July
Available in retail stores around the world in the coming months.

MSRP $149.95 USD

IMAGERY

Images of all products are available for download HERE.

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity and audio solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people through technology whether at home, at work or on a new adventure. In 2018, Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remains forever inspired by people and the planet we live on.

© 2022 Belkin International, Inc. and/or its affiliates. All rights reserved.
All product names, logos, and brands are property of their respective owners.

_____________________________________

* Fast charging is only compatible with Apple Watch Series 7. Other models will have regular charge times.

** Based on testing conducted by Belkin in October 2021 using Apple Watch Series 7 (GPS) 45mm Aluminum with Sport band and Apple Watch Series 6 44mm Aluminum with Sport band (GPS), all devices tested with watchOS 8.0.1 software, Belkin BOOSTCHARGE PRO Portable Fast Charger for Apple Watch/Belkin BOOSTCHARGE PRO 3-in-1 Wireless Charging Pad with MagSafe and Apple 20W USB-C Power Adapter (Model A2305). Charge time varies with region, settings, and environmental factors; actual results will vary.

*** For iPhone 13 mini and iPhone 12 mini, MagSafe charging delivers up to 12W of peak power delivery.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jen Wei
Vice President of Global Communications and Corporate Development
comms@belkin.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release

IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional

PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release

Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom